Help Develop New Treatments
Researchers need help from people with Ataxia to look for a cure and develop new treatments. Here are things that you can do to be a part of the fight against Ataxia.
Patient Registries are essential tools for Ataxia researchers. The purpose of a patient registry is to advance the development of treatments for a disease by connecting researchers with those who are affected with that disease. If you or a family member are affected by Ataxia or are at risk for Ataxia, we recommend that you sign up on the appropriate patient registry listed below (you can be included on more than one patient registry.)
Ataxia Patient Registry at CoRDS The CoRDS Registry was established to facilitate the establishment of rare disease registries for all rare diseases with a specific questionnaire for those with any type of ataxia or those at risk for Ataxia.
Friedreich’s Ataxia Research Alliance Patient Registry for those with Friedreich’s ataxia.
The Fragile X Research Registry is for families who have individuals with Fragile X-associated tremor/ataxia syndrome (FXTAS) in the United States.
Autosomal recessive spastic ataxia of Charlevoix-Saguenay ARSACS The purpose of this website is to create a new database for the SACSIN gene mostly reported in the province of Quebec, Canada.
Ataxia-Telangiectasia (A-T) Children’s Project Family Data Base is to help A-T families stay in touch with the A-T Children’s Project for information about clinical studies.
Participating in a clinical trial is one way to take an active role in furthering understanding and treatment of Ataxia. It is also a way to get access to new treatment options before they are widely available. However, participating in a clinical trial is a deeply personal choice to make. Look into risks and benefits of each trial before enrolling. The following links are great resources for finding research studies that are looking for volunteer participants.
- ClinicalTrials.gov: Provides updated information about federally and privately supported clinical research
- Clinical Research Consortium for the SCA’s
The following links will provide information about participating in a clinical trial.
The National Ataxia Foundation is committed to providing information to those affected by ataxia including the availability of research studies and clinical trials for the study of ataxia.
Below you will find clinical trials and research opportunities for those with various types of ataxia. These trials have been approved and monitored by an Institutional Review Board (IRB) to make sure the risks are as low as possible and are worth any potential benefits.
- An updated IRB approved clinical study at Weill Cornell Medical College on Friedreich’s Ataxia is recruiting individuals located anywhere in the United States, not just locally in the NYC area, between the ages of 18-30.
- A Phase II, Open Label Prospective Single Center Drug Study Evaluating the Safety and Efficacy of (+)-Epicatechin in Subjects With Friedreich’s Ataxia
- An Open-label Trial of Intravenous Immune Globulin in Treating SCAs
- Do you have Cerebellar Ataxia? Would you like to participate in a sleep study?
- Individuals with SCA1, SCA2, SCA3, SCA6, SCA8 needed for research study at Johns Hopkins
- Individuals with SCA6 and SCA8 are Needed to Participate in Research Studying Ataxic Movements at the Kennedy Krieger Institute
- Ataxia research project at the University of California, Berkeley
- Natural History of Spinocerebellar Ataxia Type 7
- Recruiting participants who are at least 14 years or older who have a genetically confirmed diagnosis of SCA7
- SCA 4 & 7
- Seeking individuals for a study to better understand the brain in individuals with FXTAS
- Trial in Adult Subjects with Spinocerebellar Ataxia types 1,2,3,6,7,8 and 10
- Two-part study to evaluate the efficacy, safety, and pharmacodynamics of RTA 408 in the treatment of patients with Friedreich’s ataxia
- MOXIe Clinical Study by Reata – For evaluating the safety and effectiveness of omaveloxolone for the treatment of Friedreich’s Ataxia
One of the challenges in developing a treatment for a rare disease, such as Ataxia, is the lack of natural history studies. A natural history study collects data that shows how a specific disease progresses in individuals over time. Natural history studies are essential for developing clinical trial designs that will facilitate drug development.With the recent funding by the National Ataxia Foundation of the Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA), a natural history study will begin for SCAs 1, 2, 3, 6 and 7 (and SCA 8 and 10 at some sites). The institutions and principle investigators that are in the CRC-SCA are listed below:
- Columbia University – Dr. Sheng Han Kuo
- Emory University – Dr. George (Chip) Wilmot
- Houston Methodist Research Institute – Dr. Tetsuo Ashizawa
- Johns Hopkins University – Drs. Liana Rosenthal and Chiadikaobi Onyike
- Massachusetts General – Dr. Jeremy Schmahmann
- Northwestern University – Dr. Puneet Opal
Contact: Karen Williams 312-503-2068
- University of California – Dr. Susan Perlman
- University of Chicago – Dr. Christopher Gomez
- University of Florida – Dr. SH Subramony
- University of Michigan – Drs. Henry Paulson and Vikram Shakkottai
- University of Minnesota – Dr. Khalaf Bushara
- University of Utah – Dr. Stefan Pulst
The success of the natural history study is dependent on participation by individuals who have those forms of SCA. If you have SCA 1, 2, 3, 6 or 7 (and SCA 8 and 10 at some sites) and are a patient at one of those sites or can travel to a site, please contact the clinic office for more information. You may also contact Sue Hagen at NAF at 763-231-2742 or email@example.com for more information.
Donating tissue for medical research is an important and deeply personal decision. Proper planning can help ensure that wishes are accounted for and honored at the time of your or a loved one’s passing. For additional information on tissue donation, contact the National Ataxia Foundation at firstname.lastname@example.org or call 763-553-0020. Thank you for considering this important legacy gift.